FDA Approves AFATINIB — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. has secured FDA approval for the ANDA for afatinib dimaleate, which positions the company to enter the oral anticancer market. This approval could bolster Camber's generic revenue stream and intensify competition for the brand's exclusivity period.